The first case of phage therapy for biliary tract infection caused by superbugs!
Tsinghua University PressPeer-Reviewed Publication
Biliary tract infections (BTI), often linked to structural abnormalities like bile duct stones, pose significant treatment challenges due to drug-resistant bacteria like Pseudomonas aeruginosa. Phage therapy, which uses viruses to target bacteria, has emerged as a promising solution. This study by researchers from Fudan University and Army Medical University, published in hLife, reported the first successful use of personalized phage therapy for chronic BTI caused by multidrug-resistant P. aeruginosa. An 88-year-old patent with recurrent infections underwent phage therapy after traditional treatments failed. A customized phage cocktail was administered, leading to symptom improvement and reduced bacterial load. However, phage-resistant strains emerged, prompting a second round of therapy with a different phage, which further alleviated symptoms. Genomic analysis revealed bacterial mutations contributing to resistance. This study highlights the potential of phage therapy for treating drug-resistant infections, though challenges like bacterial heterogeneity and biofilm formation remain. Future research aims to optimize phage therapy strategies for better outcomes.
- Journal
- hLife